文献速递糖尿病

导致MT2信号减弱的罕见MTNR1B变异与HbA1c水平升高相关但与2型糖尿病无关

Rare MTNR1B variants causing diminished MT2 signalling associate with elevated HbA1c levels but not with type 2 diabetes.
PubMed 文献 · Diabetologia · 2025-03-10

在UK Biobank、丹麦Inter99和DD2队列中开展横断面研究及基因型召回研究,发现导致MT2信号减弱的MTNR1B错义变异携带者HbA1c水平升高(β 0.087 SD),但2型糖尿病患病率无显著关联。 melatonin刺激后携带者胰岛素反应降低。

要点

  • 导致MT2信号减弱的MTNR1B错义变异携带者HbA1c较非携带者升高(β 0.087 SD)。
  • UK Biobank中MTNR1B变异与2型糖尿病患病率无显著关联。
  • melatonin处理后,MT2信号减弱变异携带者胰岛素反应降低(β -476.0)。

核心结论

  • 导致MT2信号减弱的MTNR1B错义变异携带者既往观察到的2型糖尿病患病率升高未在UK Biobank中复制,但携带者HbA1c水平升高。

研究设计与样本

  • 横断面研究,在UK Biobank中进行MTNR1B变异负荷检验:血糖表型N=248,454(无糖尿病),其他心血管代谢表型N=330,453,2型糖尿病患病率病例对照研究N=263,739。
  • 在丹麦Inter99无糖尿病参与者(N=5711)中进行类似血糖表型负荷检验,并在DD2队列(病例N=2930)与Inter99(对照N=4243)中检验2型糖尿病患病率。
  • 基因型召回研究评估MTNR1B变异对melatonin诱导的血糖调节反应的影响,对象为无糖尿病个体。

主要发现

  • UK Biobank中,MTNR1B变异与心血管代谢表型(包括2型糖尿病患病率)无关联,但导致MT2信号减弱的错义变异携带者HbA1c较非携带者升高(效应量β 0.087 SD [95% CI 0.039, 0.135])。
  • Inter99人群中,血糖相关表型无显著关联,但MT2信号减弱变异携带者显示名义显著较低的葡萄糖刺激胰岛素反应(β -0.47 SD [95% CI -0.82, -0.11])。
  • melatonin处理后,MT2信号减弱变异携带者(β -476.0 [95% CI -928.6, -24.4])或rs10830963变异携带者(β -390.8 [95% CI -740.1, -41.6])较非携带者胰岛素反应降低。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: An intronic variant (rs10830963) in MTNR1B (encoding the melatonin receptor type 2 [MT2]) has been shown to strongly associate with impaired glucose regulation and elevated type 2 diabetes prevalence. However, MTNR1B missense variants have shown conflicting results on type 2 diabetes. Thus, we aimed to gain further insights into the impact of MTNR1B coding variants on type 2 diabetes prevalence and related phenotypes. METHODS: We conducted a cross-sectional study, performing MTNR1B variant burden testing of glycaemic phenotypes (N=248,454, without diabetes), other cardiometabolic phenotypes (N=330,453) and type 2 diabetes prevalence (case-control study; N=263,739) in the UK Biobank. Similar burden testing with glycaemic phenotypes was performed in Danish Inter99 participants without diabetes (N=5711), and type 2 diabetes prevalence (DD2 cohort serving as cases [N=2930] and Inter99 serving as controls [N=4243]). Finally, we evaluated the effects of MTNR1B variants on the melatonin-induced glucose regulation response in a recall-by-genotype study of individuals without diabetes. RESULTS: In the UK Biobank, MTNR1B variants were not associated with cardiometabolic phenotypes, including type 2 diabetes prevalence, except that carriers of missense MTNR1B variants causing impaired MT2 signalling exhibited higher HbA1c levels compared with non-carriers (effect size, β, 0.087 SD [95% CI 0.039, 0.135]). Similarly, no significant associations were observed with phenotypes associated with glycaemic phenotypes in the Inter99 population. However, carriers of variants impairing MT2 signalling demonstrated a nominally significant lower glucose-stimulated insulin response (β -0.47 SD [95% CI -0.82, -0.11]). A reduced insulin response was also observed in carriers of variants impairing MT2 signalling (β -476.0 [95% CI -928.6, -24.4]) or the rs10830963 variant (β -390.8 [95% CI -740.1, -41.6]) compared with non-carriers after melatonin treatment. CONCLUSIONS/INTERPRETATION: The higher type 2 diabetes prevalence previously observed in carriers of missense MTNR1B variants causing impairment in MT2 signalling was not replicated in the UK Biobank, yet carriers had elevated HbA1c levels. DATA AVAILABILITY: Data (Inter99 cohort and recall-by-genotype study) are available on reasonable request from the corresponding author. Requests for DD2 data are through the application form at https://dd2.dk/forskning/ansoeg-om-data . Access to UK Biobank data can be requested through the UK Biobank website ( https://www.ukbiobank.ac.uk/enable-your-research ).

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Sørensen KV, Justesen JM, Ängquist L, et al. Rare MTNR1B variants causing diminished MT2 signalling associate with elevated HbA1c levels but not with type 2 diabetes. Diabetologia. 2025. PMID: 40064676. doi:10.1007/s00125-025-06381-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。